We can judge whether KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) is a good investment right now by following the lead of some of the best investors in the world and piggybacking their ideas. There's no better way to get these firms' immense resources and analytical capabilities working for us than to follow their lead into their best […]
We often see insiders buying up shares in companies that perform well over the long term. Unfortunately, there are...
Prospects Appear Bright for Small Drug Industry in 2020
BioLineRx (BLRX) closes patient recruitment in the triple combination arm of the phase IIa COMBAT/KEYNOTE-202 study on Motixafortide to treat second-line metastatic pancreatic cancer.
Corcept Therapeutics (CORT) reports in-line earnings in the fourth quarter of 2020.
The worst result, after buying shares in a company (assuming no leverage), would be if you lose all the money you put...
In 2016 Andy Crockett was appointed CEO of KalVista Pharmaceuticals, Inc. (NASDAQ:KALV). This analysis aims first to...
KalVista Pharmaceuticals, Inc. (NASDAQ:KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of small molecule protease inhibitors, today announced potential impact of coronavirus disease 2019 (COVID-19) on its ongoing operations and provided revised financial guidance that activities are funded into at least early 2022.
As of late, it has definitely been a great time to be an investor in KalVista Pharmaceuticals.
Their low debt-equity ratio reduces the investment risk Continue reading...
The Zacks Analyst Blog Highlights: Calavo Growers, Darling Ingredients, The Simply Good Foods Company, KalVista Pharmaceuticals and CareDx
Here are five defensive stocks that can shield your portfolio as Covid-19 continues to spread, instilling volatility in the stock market.
Here are five defensive stocks that can shield your portfolio from China's coronavirus that intimidates to weigh on the stock market.
KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of small molecule protease inhibitors, today announced that it will present at the Needham Virtual Healthcare Conference on Wednesday, April 15, 2020, at 11:20 a.m. ET.
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week highs on Feb. 10) AbbVie Inc (NYSE: ABBV ) Allergan plc (NYSE: AGN ) ...
The FDA accepts FibroGen's (FGEN) NDA for roxadustat for the treatment of anemia of chronic kidney disease in both non-dialysis-dependent and dialysis-dependent patients.
KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of small molecule protease inhibitors, today provided an operational update and released financial results for the fiscal third quarter ended January 31, 2020.
The Zacks Analyst Blog Highlights: ResMed, Ensign, DaVita, KalVista Pharmaceuticals and MEI Pharma
Pacira (PCRX) beats earnings estimates in the fourth quarter of 2019. Revenues are in line with estimates.